Teva Pharmaceuticals Acquires Emalex Biosciences

Teva Pharmaceuticals has acquired Emalex Biosciences in a definitive transaction to add ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome, to Teva’s neuroscience pipeline. The deal includes $700 million paid at closing, with up to $200 million in additional commercial milestone payments and net sales-based royalties, subject to regulatory approval.